Lundbeck executive: I knew FDA had another opinion
It is yet uncertain whether Lundbeck, for the third time, will try to win an updated label for antidepressant Trintellix in the US, says Anders Gersel Pedersen, Lundbeck’s executive vice president for research and development. Last week's rejection from FDA came as no surprise to him.
BY LONNI PARK LYNGE
Second time was not the charm for Denmark's Lundbeck and its partner Takeda in their bid to expand the label for antidepressant Trintellix to include effects on cognition for patients with major depression disorder.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Clinical surprise for Lundbeck
For abonnenter
Lundbeck CEO: two to three projects will fail every year
For abonnenter
